ACE Technology Guidances

ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 31 Aug 2022
Last Updated on 31 Aug 2022
A- A+
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has recommended:
  • Tepotinib 225 mg tablet

for treating metastatic mesenchymal epithelial transition exon 14 skipping (METex14sk) mutation-positive non-small-cell lung cancer (NSCLC) in line with specific clinical criteria.

Funding status

Tepotinib 225 mg tablet is recommended for inclusion on the MOH Cancer Drug List (CDL; MAF with MediShield Life monthly claim limit of $1,600) for the abovementioned indication from 1 September 2022.    

CDL listing does not apply to any formulations or strengths of capmatinib for treating metastatic METex14sk mutation-positive NSCLC.

Clinical indications, subsidy class and MediShield Life claim limits for all drugs included in the evaluation are provided in the Annex.

Tyrosine kinase inhibitors for MET mutation-positive metastatic NSCLC (31 Aug 22) Treatments for MET exon 14 skipping mutated metastatic NSCLC PES (31 Aug 22)